NantHealth (NH) Rating Increased to Hold at BidaskClub

BidaskClub upgraded shares of NantHealth (NASDAQ:NH) from a sell rating to a hold rating in a report published on Tuesday.

Several other analysts also recently commented on NH. Zacks Investment Research upgraded NantHealth from a hold rating to a buy rating and set a $4.25 target price on the stock in a research note on Thursday, January 11th. Jefferies Group reiterated a buy rating and set a $5.00 target price on shares of NantHealth in a research note on Thursday, September 28th. Finally, Canaccord Genuity cut their target price on NantHealth from $6.00 to $5.00 and set a buy rating on the stock in a research note on Friday, November 17th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus target price of $8.05.

NantHealth (NASDAQ:NH) traded up $0.18 during trading on Tuesday, hitting $3.95. The company had a trading volume of 526,800 shares, compared to its average volume of 225,050. The company has a debt-to-equity ratio of 0.93, a current ratio of 2.38 and a quick ratio of 2.36. The stock has a market cap of $408.40, a P/E ratio of -2.22 and a beta of -1.50. NantHealth has a 52 week low of $2.60 and a 52 week high of $10.02.

NantHealth (NASDAQ:NH) last issued its earnings results on Thursday, November 9th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.01. NantHealth had a negative return on equity of 46.09% and a negative net margin of 225.76%. The business had revenue of $21.76 million for the quarter, compared to the consensus estimate of $29.42 million. During the same period last year, the business posted ($0.18) EPS. The company’s revenue was up 5.3% compared to the same quarter last year. research analysts predict that NantHealth will post -1.35 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NH. Bank of New York Mellon Corp lifted its holdings in shares of NantHealth by 194.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 44,849 shares of the company’s stock valued at $190,000 after buying an additional 29,639 shares during the period. Alliancebernstein L.P. bought a new position in shares of NantHealth during the 2nd quarter valued at $102,000. Teachers Advisors LLC lifted its holdings in shares of NantHealth by 351.8% during the 2nd quarter. Teachers Advisors LLC now owns 31,578 shares of the company’s stock valued at $134,000 after buying an additional 24,588 shares during the period. TIAA CREF Investment Management LLC lifted its holdings in shares of NantHealth by 136.9% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 47,848 shares of the company’s stock valued at $202,000 after buying an additional 27,648 shares during the period. Finally, GSA Capital Partners LLP bought a new position in shares of NantHealth during the 2nd quarter valued at $121,000. 7.10% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This story was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.tickerreport.com/banking-finance/3142745/nanthealth-nh-rating-increased-to-hold-at-bidaskclub.html.

About NantHealth

NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.

Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.